Equity Overview
Price & Market Data
Price: $2.80
Daily Change: +$0.35 / 12.50%
Range: $2.45 - $3.05
Market Cap: $228,648,848
Volume: 2,110,584
Performance Metrics
1 Week: 118.8%
1 Month: 218.2%
3 Months: 244.8%
6 Months: 156.9%
1 Year: 47.37%
YTD: 229.4%
Company Details
Employees: 32
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.